KKR, a global investment firm, and Impilo, a Nordic healthcare investment firm, have announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products.
Having announced the strategic partnership in April this year, KKR and Impilo will continue to work together with Immedica’s experienced management team to support the business’ growth, as it continues to build on its position as a leader in the European rare disease space.
KKR invested in Immedica through its KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies. KKR has a long track record of supporting health care companies globally, having invested approximately $20 billion in the sector since 2004.
Impilo re-invested into Immedica through a continuation fund which will enable Impilo to continue supporting Immedica with additional equity alongside KKR.
Kugan Sathiyanandarajah, Partner and Head of KKR’s Health Care Strategic Growth business in Europe, commented, “We are excited to close the transaction with Immedica, alongside Impilo. We remain committed to supporting Immedica’s future growth as a rare disease player with a highly promising pipeline and attractive international expansion prospects.”
Magnus Edlund, Partner at Impilo, commented, “We are eager to now embark on the next phase of Immedica’s growth journey together with KKR and management, making innovative medicines available to more patients with high unmet medical needs.”
Anders Edvell, CEO of Immedica, commented, “This collaboration with KKR and Impilo marks an exciting step forward in our mission to deliver innovative treatments to more patients with rare diseases. With their support, we are well-positioned to enhance our growth and continue addressing critical unmet medical needs across the globe.”
Since its founding in 2018 by Impilo, Immedica has built an impressive portfolio and pipeline of drugs primarily within haematology, oncology and genetic & metabolic diseases for rare conditions with high unmet medical needs, generating revenues of EUR 100m and annual growth of more than 50%.
